Quiz

Quiz Topic: Lung Cacer SBRT (IAEA)

Question 1 of 10: Which of the following is a recent technical enhancement that has significantly improved the precision of SBRT equipment for lung cancer treatment?

Introduction of helical tomotherapy Use of cobalt-60 based machines Advent of robotic radiosurgery systems Revival of orthovoltage x-ray therapy

Question 2 of 10: What is a typical criterion for selecting lung cancer patients suitable for SBRT?

Tumors located centrally within the thorax Medically inoperable patients with peripherally located tumors less than 5 cm in diameter Patients with extensive nodal involvement Patients who decline surgical treatment regardless of tumor characteristics

Question 3 of 10: How does local control in early-stage non-small cell lung cancer compare between SBRT and conventional radiotherapy?

SBRT demonstrates significantly lower local control Conventional radiotherapy shows slightly better local control SBRT and conventional radiotherapy have equivalent local control SBRT demonstrates significantly higher local control

Question 4 of 10: What is the typical sequence of therapies when integrating SBRT with systemic treatments for non-small cell lung cancer?

SBRT followed by adjuvant chemotherapy Concurrent chemoradiation followed by SBRT Neoadjuvant chemotherapy followed by SBRT Concurrent chemotherapy with SBRT

Question 5 of 10: What is one of the common strategies to manage radiation pneumonitis, a potential side effect of lung cancer SBRT?

Administration of prophylactic antiemetics Routine use of invasive ventilation Steroid therapy for symptomatic treatment Implementation of hyperbaric oxygen therapy

Question 6 of 10: What imaging technology advancement has most improved dose distribution accuracy in SBRT for lung cancer?

Standard 2D x-ray imaging First-generation CT scanners 4D CT imaging with respiratory gating PET imaging for better tumor visualization

Question 7 of 10: For which stage of lung cancer is SBRT NOT typically considered a standard treatment option?

Stage I Stage II with limited nodal involvement Stage II with extensive nodal involvement Stage IIIA with resectable tumor and limited nodal spread

Question 8 of 10: What is an emerging area of research in SBRT for lung cancer treatment?

The reduction of SBRT treatment sessions to a single fraction The use of SBRT for benign lung conditions The development of SBRT treatment planning based on historical data Utilization of nanoparticles to enhance radiation dose delivery

Question 9 of 10: How does the combination of SBRT and immune checkpoint inhibitors potentially benefit patients with non-small cell lung cancer?

It has no impact on the immune response to the tumor It may diminish the immune response making cancer more resistant to treatment It may potentiate the abscopal effect and enhance systemic immune response It specifically targets tumor cells, bypassing the immune system

Question 10 of 10: What is a known impact of implementing SBRT in the treatment of oligometastatic non-small cell lung cancer?

It has not shown any improvement in prognosis as compared to conventional therapies It significantly worsens patient quality of life due to increased toxicity It may provide local control of metastases and potentially improve survival It increases the risk of developing additional metastatic lesions

Score: